Recent advances in technology have enabled ultrasensitive detection of plasma-derived phosphorylated-tau (p-tau) levels as a potential minimally-invasive Alzheimer’s disease (AD) biomarker [1–4]. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.